Crinetics Pharmaceuticals
CRNX
62 hedge funds and large institutions have $404M invested in Crinetics Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 25 increasing their positions, 9 reducing their positions, and 4 closing their positions.
300% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 4
178% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 9
24% more funds holding
Funds holding: 50 → 62 (+12)
3.77% more ownership
Funds ownership: 69.83% → 73.6% (+3.8%)
20% less capital invested
Capital invested by funds: $503M → $404M (-$99.7M)
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$16.6M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$6.41M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.41M |
| 4 |
BlackRock
New York
|
+$2.08M |
| 5 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$1.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$10.2M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$2.86M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
-$1.02M |
| 4 |
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
|
-$330K |
| 5 |
TD Asset Management
Toronto,
Ontario, Canada
|
-$288K |
CRNX Hedge Fund Activity: Q1 2019 in Review
62 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Crinetics Pharmaceuticals (CRNX) for Q1 2019, worth a combined $404M — down 20% from $503M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new CRNX positions and 4 closed out — a net gain of 12 holders — while 25 added to existing stakes and 9 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $16.6M. The largest seller was Vivo Capital, cutting an estimated $10.2M.
- 62 institutional investors held Crinetics Pharmaceuticals (CRNX) as of Q1 2019, up from 50 in Q4 2018.
- Funds reported $404M of Crinetics Pharmaceuticals stock for Q1 2019, down 20% quarter-over-quarter.
- 16 funds opened new Crinetics Pharmaceuticals positions in Q1 2019 and 4 closed out, a net change of +12 holders.
- The largest Crinetics Pharmaceuticals buyer in Q1 2019 was Fidelity Investments, an estimated $16.6M added.
- The largest Crinetics Pharmaceuticals seller in Q1 2019 was Vivo Capital, an estimated $10.2M sold.
Based on aggregated 13F filings for Q1 2019.